1 Detection of Bourbon virus specific serum neutralizing antibodies in human serum

2 in Missouri, USA

- 3
- 4 Gayan Bamunuarachchi^{1,#}, Houda Harastani^{1,#}, Paul W. Rothlauf^{3,6,#}, Ya-nan Dai⁴, Ali, Ellebedy⁴,
- 5 Daved Fremont^{4,5}, Sean P.J. Whelan³, David Wang^{3,4}, Adrianus C. M. Boon^{1,3,4}.
- 6
- ⁷ ¹ Department of Medicine, ³ Department of Molecular Microbiology, ⁴ Department of Pathology and
- 8 Immunology, and ⁵ Department of Biochemistry and Molecular Biophysics, at Washington
- 9 University School of Medicine in St. Louis.
- ⁶Program in Virology, Harvard Medical School, Boston, MA, USA.
- [#] Equal contribution
- 12
- 13 Lead Contact
- 14 Adrianus C. M. Boon
- 15 Department of Internal Medicine
- 16 Washington University in Saint Louis
- 17 School of Medicine
- 18 St. Louis, MO 63110
- 19 Email: jboon@wustl.edu
- 20 Running Title: Detection of Bourbon virus neutralizing antibody in human serum
- 21 Keywords: Bourbon virus, Seroprevalence, Human serum, Glycoprotein, monoclonal antibody,
- 22 Virus neutralization

23 ABSTRACT

Bourbon virus (BRBV) was first discovered in 2014 in a fatal human case. Since then 24 it has been detected in the Amblyomma americanum tick in the states of Missouri and 25 Kansas in the United States. Despite the high prevalence of BRBV in ticks in these states, 26 very few human cases have been reported, and the true infection burden of BRBV in the 27 community is unknown. Here, we developed two virus neutralization assays, a VSV-28 BRBV pseudotyped rapid assay, and a BRBV focus reduction neutralization assay, to 29 assess the seroprevalence of BRBV neutralizing antibodies in human sera collected in 30 31 2020 in St. Louis, Missouri. Out of 440 human serum samples tested, three (0.7%) were able to potently neutralize both VSV-BRBV and wild type BRBV. These findings suggest 32 that human infections with BRBV are more common than previously recognized. 33

34 **Importance**

Since the discovery of the Bourbon virus (BRBV) in 2014, a total of five human cases 35 have been identified, including two fatal cases. BRBV is thought to be transmitted by the 36 Lone Star tick, which is prevalent in the East, Southeast, and Midwest of the United States 37 (US). BRBV has been detected in ticks in Missouri and Kansas and serological evidence 38 suggests that it is also present in North Carolina. However, the true infection burden of 39 BRBV in humans is not known. In the present study, we developed two virus neutralization 40 assays to assess the seroprevalence of BRBV specific antibodies in human sera collected 41 in 2020 in St. Louis, Missouri. We found that a small subset of individuals is seropositive 42 for neutralizing antibodies against BRBV. Our data suggest that BRBV infection in 43 humans is more common than previously thought. 44

45

46 **INTRODUCTION**

Emerging and reemerging infectious diseases cause substantial global health and 47 socio-economic burden, and have a significant impact on human and animal life. Viral 48 pathogens, like Ebola virus, severe acute respiratory syndrome coronavirus-2 (SARS-49 CoV-2), influenza virus, and Chikungunya virus, are among the most prominent emerging 50 51 zoonotic infections [1]. Many zoonotic diseases are transmitted by arthropod vectors such as mosquitos and ticks and are an important cause of human morbidity and mortality in 52 the United States (US). Ticks are the main vector that transmit pathogens in the US 53 54 including four different viruses; Powassan virus, Colorado tick fever virus, Heartland virus (HRTV), and Bourbon virus (BRBV). 55

BRBV belongs to the family Orthomyxoviridae, genus Thogotovirus. BRBV is a 56 negative-sense segmented RNA virus whose genome is composed of 6 gene segments 57 [2]. Segment 4 encodes the viral envelope glycoprotein (GP) that is necessary for virus 58 attachment and entry into cells [3], and it is the main target for virus neutralizing antibodies 59 [4]. A total of five human BRBV cases, including two fatal cases, have been reported since 60 the discovery of this virus in 2014. The first case of BRBV was an adult male patient from 61 62 Bourbon County, Kansas, USA. The patient was hospitalized with febrile illness and later died from renal failure and acute respiratory distress syndrome. Subsequent culturing and 63 64 next-generation sequencing of the blood of this patient identified BRBV [5]. In 2017, a 65 state park official from Missouri was diagnosed positive for BRBV. This patient later died of respiratory failure and cardiac complications [2, 6]. Both patients had reported tick 66 exposure and bites prior to becoming ill [2, 5]. 67

medRxiv preprint doi: https://doi.org/10.1101/2022.03.17.22272570; this version posted March 18, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

BRBV is isolated from lone star ticks (Amblyomma americanum) [7-10]. These ticks 68 are abundant and aggressive human-biting ticks that are widely distributed across the 69 East, Southeast, and Midwest US [8, 11]. Rabbits fed on by BRBV-infected ticks 70 developed high antibody titers to the virus suggesting the lone star tick is a competent 71 vector of BRBV [10]. BRBV neutralizing antibodies have been identified in different wild 72 73 animal species. Using plaque-reduction neutralization test (PRNT), 50% and 86% seroprevalence of BRBV neutralizing antibodies was found in sera from raccoons and 74 white-tailed deer in Missouri respectively [12]. Moreover, 56% seroprevalence was 75 observed in white-tailed deer sera from North Carolina [13]. These observations 76 demonstrate that the rate of infection of wild animals is significant, raising questions as to 77 the true infection rate and clinical burden of BRBV in humans. 78

Serology can provide an important benchmark on population immunity against pathogens. However, to date there have been no serosurveillance studies assessing the seroprevalence of BRBV specific neutralizing antibodies in humans in the US and world. Thus the objectives of our study were to develop BRBV neutralization assays and measure the human seroprevalence of BRBV infection. We found that nearly 1% of the human sera, obtained in 2020, contained BRBV neutralizing antibodies. These data suggest that BRBV infection in people is more common than previously thought.

86 MATERIALS AND METHODS

Virus and cell culture. Vero E6 and Vero-CCL81 cells were maintained in Dulbecco's 87 Modified Eagle Medium (DMEM) containing 4.5 g/L glucose, L-glutamine, and sodium 88 pyruvate (Corning) and supplemented with 10% Fetal Bovine Serum (FBS). Vero E6 cells 89 (ATCC) were grown in DMEM media (Corning Cellgro) supplemented with 5% FBS 90 (Biowest), 100 U/mL Penicillin (Life Technologies), 100 µg/mL streptomycin (Life 91 Technologies), and 2 mM L-Glutamine (Corning). Expi293F cells (Thermo Fisher 92 Scientific) used for transfection were maintained in Expi293 Expression Medium (Gibco). 93 VSV-eGFP-BRBV (herein VSV-BRBV) was generated by replacing the endogenous 94 G gene in a molecular cDNA of vesicular stomatitis virus (VSV), encoding eGFP, with a 95 codon-optimized version of the BRBV GP gene (Original strain, Kansas, Genbank 96 AMN92169.1). Virus rescue was performed as described [14]. Briefly, BSRT7/5 cells were 97 infected with vaccinia virus vTF7-3 and subsequently transfected with T7-driven helper 98 plasmids encoding VSV N, P, L, and G, and the VSV-BRBV cDNA. Cell supernatants 99 were harvested after 72 hours, centrifuged at 1,000 x g for 5 min, and passed through a 100 0.22 µm filter. Vero-CCL81 cells were then infected with rescue supernatants, and 101 102 plaques in agarose plugs were isolated and passed to Vero-CCL81 cells for p1 stock generation. Working stocks were obtained by growing VSV-BRBV on Vero-CCL81 cells 103 at a multiplicity of infection of 0.01. RNA was extracted from virus stocks using the 104 105 QIAamp Viral RNA Mini Kit. RNA was reverse-transcribed using the QIAGEN OneStep RT-PCR Kit with primers targeting VSV M-G (forward) and G-L (reverse) intergenic 106 regions. Stock sequences were confirmed by Sanger sequencing. BRBV (strain BRBV-107

STL) [2] was grown on Vero E6 cells. Virus stocks were sequenced by next generation,
 aliquoted, stored at -80°C, and used for all subsequent studies.

VSV-BRBV characterization. Vero-CCL81 cells were infected with eGFP-expressing
VSV (herein referred to as VSV) or VSV-BRBV at an MOI of 1. Cells were imaged 6 hours
post infection (hpi). Plaque assays were performed by infecting Vero-CCL81 cells with
the aforementioned viruses for 1 h at 37°C, after which the inoculum was removed, and
cells were overlayed with an agarose-containing overlay. Plates were imaged 24 hpi using
a biomolecular imager in the FITC channel.

Recombinant proteins. Recombinant BRBV GP (rGP, residues 20-485) was 116 expressed using the baculovirus expression system or transiently expression in 117 mammalian cell lines. For expressing with baculovirus expression system, the gene block 118 of BRBV GP ectodomain followed trimerization 119 by а sequence (GYIPEAPRDGQAYVRKDGEWVLLSTFL) from the bacteriophage T4 fibritin and 6*His 120 tag at the extreme C-terminal was cloned into a modified pOET1 (Mirus Bio) baculovirus 121 transfer vector containing green fluorescent protein as an indicator [15]. Transfection and 122 amplification were carried out according to the *flash*BAC baculovirus expression system 123 manual (Mirus Bio). The High Five[™] (Gibco) cell culture supernatant was harvested after 124 72 hpi, and concentrated before dialysis against buffer 20 mM NaHCO₃, 300 mM NaCl, 125 pH 8.0. BRBV GP ectodomain was captured by passaging the supernatant over Ni²⁺ 126 affinity resin (GoldBio) and eluted with 500 mM imidazole (Sigma-Aldrich). The recovered 127 proteins were further applied to HiLoad 16/600 Superdex 200 column (GE healthcare) in 128 20 mM HEPES, 150 mM NaCl, and pH of 7.5. For expression in mammalian cells, the 129 gene fragment harboring the ectodomain, the trimerization domain as well as 6x-His tag 130

from the recombinant baculovirus vector was cloned into pFM1.2R vector [16] and transiently expressed in Expi293F cells. The cell culture supernatant was harvested after 5 days post-transfection and concentrated before dialyzing against buffer 20 mM Tris-Cl pH 8.5, 150 mM NaCl. Then the BRBV GP ectodomain protein was purified with the same strategy as described above, with a combination of Ni affinity chromatography and size exclusion chromatography.

Animal experiments. All animal experiments were preformed according to the 137 Institutional Animal Care and Use Committee (IACUC) at Washington University in St. 138 Louis. Eleven-to-twelve weeks-old female C57BL/6 mice were obtained from Jackson 139 Laboratories. Mice (n = 3) were immunized intramuscularly with 500 ng of Beta-140 propiolactone (BPL; Sigma-Aldrich) inactivated and purified BRBV complemented with 141 addavax (InvivoGen) (1:1, v:v) to generate BRBV GP specific monoclonal antibodies 142 (mAb). Four weeks later, the mice were immunized intramuscularly with 5 µg of 143 baculovirus-derived recombinant GP of BRBV complemented with addavax (1:1, v:v). 144 Sera was collected one day prior to each immunization and stored at -20°C. To generate 145 positive control sera, containing BRBV-specific neutralizing antibodies, we infected 146 C57BL/6 mice with 10⁴ infectious units of BRBV and collected sera at 22 days post 147 infection. Sera from five BRBV-infected mice were pooled together to use as the positive 148 control in the virus neutralization assays. 149

Flow cytometry. For B cell staining, spleen cells were collected five days post final
 immunization and stained for 30 min on ice with CD16/CD32 (93; Biolegend[®] 1:100) and
 biotinylated mammalian expressed rGP (1:100) diluted in PBS supplemented with 2%
 FBS and 2 mM EDTA (P2). Next, the cells were washed twice with P2 and stained for 30

min on ice with anti-CD19-FITC (1D3; BioLegend® 1:100), anti-IgD-APC-Cy7-A (11-154 26c.2a; BioLegend® 1:100), anti-Fas-PE-A (Jo2; BD Biosciences 1:200), anti-GL7-155 PerCP-Cy5.5-A (GL7; BioLegend[®] 1:50), anti-CD71-PE-Cy7-A (RI7217; BioLegend[®] 156 1:100), anti-CD138-BV421 (281-2; BioLegend[®] 1:100), anti-CD4-AF700 (GK1.5; 157 BioLegend[®] 1:100) and Zombie Aqua (BioLegend[®] 1:200) diluted in Brilliant Stain buffer 158 (BD Horizon). After 30 min, the cells were washed twice with P2, after which they were 159 analyzed and single rGP-binding antibody-secreting B- cells (ASC; CD4, CD19⁺, IgD¹⁰, 160 CD95⁺, GL7⁻, CD138⁺, BRBV-GP⁺ live singlet lymphocytes) were sorted (n = 376) into 161 four 96-well plates containing 2 µL of Lysis Buffer (Clontech) supplemented with 1 U/µL 162 RNase inhibitor (New England BioLabs) with a FACSAria II and immediately frozen on 163 dry ice. Flow cytometry data were analyzed using FlowJo[™] v.10.8.1. 164

165 Monoclonal antibody production. mAbs were generated as previously described previously [17]. Briefly, variable heavy (VH) and variable light kappa and lambda (Vκ and 166 $V\lambda$, respectively) genes were amplified by RT-PCR and nested PCR from single-cell 167 sorted BRBV-GP specific ASCs using mixtures of primer sets specific for IgG, IgM/A, Igk, 168 and $Ig\lambda$ using first-round and nested primer sets PCR products were then loaded on a 1% 169 170 agarose gel (Lonza), purified and then sequenced. Sequencing data was annotated using IMGT/V-QUEST tool v3.5.28 on the ImMunoGenetTics database (available at 171 http://www.imgt.org/IMGT_vquest/) [18, 19]. Clonally related cells were identified by 172 173 similarity in variable heavy and light chain usage, CDR3 length, and amino-acid composition. To generate recombinant mAbs, heavy chain V-D-J and light chain V-J 174 175 fragments were PCR amplified from first-round PCR products with mouse variable gene 176 forward primers and joining J gene reverse primers having 59 extensions for cloning by

Gibson assembly as previously described [20] and were cloned into pABVec6W Ab expression vectors [21] in frame with either human IgG1, Igκ, or Igλ constant region. Expression plasmids were sequence verified and transfected at a 1:2 ratio of heavy to light chain ratio into Expi293F cells using the Expifectamine 293 Expression Kit (Thermo Fisher Scientific). Culture supernatant was collected seven days post transfection and mAbs, secreted into the supernatant, were purified with protein A agarose (Invitrogen), and then stored at 4°C until further used.

Enzyme-linked immunosorbent assay (ELISA). Ninety-six well microtiter plates 184 (Thermo Fisher Scientific) were coated overnight at 4°C with 1 µg/mL of baculovirus 185 expressed rGP in PBS. After washing the wells 3x with 280 µL PBS-T (PBS supplemented 186 with 0.05% Tween-20), wells were blocked with 280 µL of PBS supplemented with 10% 187 FBS and 0.05% Tween-20 (blocking buffer) for 1.5 h at room temperature (RT). Blocking 188 buffer was removed, and 3-fold serial dilutions starting from 1:30 for mouse polyclonal 189 sera or 30 µg/mL for mAbs were added and incubated for 1 h at RT. An influenza A virus 190 specific mAb (1C11) specific for the hemagglutinin of A/Puerto Rico/8/1934 was used as 191 a negative control. Plates were washed 3x with PBS-T. mAbs were detected using goat-192 193 anti-human IgG-HRP (Jackson ImmunoResearch, Cat no. 109-035-088) while mouse sera were detected using goat-anti-mouse IgG1-HRP (Southern Biotech, Cat no. 1070-194 05) diluted 1:1000 in blocking buffer for 1 h at RT. After washing 3x with PBS-T followed 195 196 by 3x with PBS, the assay was developed with 100 µL of substrate solution (phosphatecitrate buffer with 0.1% H₂O₂ and 0.4 mg/mL o-Phenylenediamine dihydrochloride (OPD, 197 198 Sigma-Aldrich)) was added to all wells and incubated for 5 min before the reaction was

stopped with 1M HCI (100 µL). Optical density measurements were taken at 490 nm using
a microtiter plate reader (BioTek).

Focus forming assay (FFA). Monolayers of Vero E6 cells, seeded in 96 well tissue 201 culture treated plates, were washed once with PBS and incubated with VSV-BRBV or 202 BRBV diluted in serum free DMEM (Corning). After 1 h at 37°C, the inoculum was 203 aspirated, the cells were washed with PBS, and 100 µL of 1% methylcellulose (Sigma) in 204 1x minimum essential media (MEM, Corning) supplemented with 2% FBS (Biowest) was 205 added to each well. The cells were incubated for 24 h at 37°C/5% CO₂ before the 206 207 monolayer was fixed with 100 µL of 5% Formalin (Fisher Chemicals) for 1 h at RT. Cells were washed with PBS and subsequently incubated with the BRBV-GP specific mAb E02 208 in PBS-T plus 1% bovine serum albumin (BSA, Sigma). After 1 h incubation at RT, the 209 210 cells were washed three times with PBS-T and incubated with HRP-conjugated goat antihuman IgG (Sigma) diluted in PBS-T + 1% BSA for 1 h at RT. Finally, cells were washed 211 three times with PBS-T, and VSV-BRBV or BRBV infected cells were visualized using 212 TMB substrate (Vector laboratories) and quantitated on an ImmunoSpot[®] Analyzer 213 (Cellular Technologies). 214

Human serum cohort. We screened 440 adult serum samples that were part of a set
of residual samples sent to Barnes-Jewish Hospital, Missouri for physician-ordered
vitamin D testing between 27 April 2020 and 12 May 2020 [22]. This study was approved
by the Human Research Protection Office at Washington University in St. Louis (approval
no. 202004199).

Rapid eGFP-based VSV-BRBV-GP virus neutralization assay. Vero E6 cells were
 cultured overnight in tissue culture treated black 96-well plates (Corning). Human sera

were heat-inactivated at 56°C for 30 min and serially diluted 1:10 and 1:30 in serum free 222 DMEM (DMEM-SF). The next day 200 focus forming units (FFU) of VSV-BRBV virus 223 diluted in an equal volume of DMEM-SF were added to the diluted human serum samples 224 (final serum dilution is 1:20 and 1:60) and incubated for 1 h at RT. Next, the antibody 225 virus complexes were added to the Vero E6 cells that were washed once with PBS and 226 227 incubated for 8 h at 37°C. Each serum sample and dilution was tested in duplicate and each assay included a positive control mouse serum sample, and no serum controls 228 (DMEM media only). After 8 h the cells were fixed with an equal volume of 10% formalin 229 230 containing 10 µg/mL Hoechst (Sigma) was added to each well for 1 h at RT. Subsequently, cells were washed once with PBS, and images were acquired with the 231 InCell 2000 Analyzer (GE Healthcare). This automated microscope contains both FITC 232 and DAPI channels to visualize infected cells (i.e. eGFP-positive cells) and nuclei 233 respectively. Each well is divided into 4 fields that are imaged with a 4x objective lens. 234 Subsequently, cumulative eGFP-positive cells and nuclei of the 4 fields were counted. 235 Images were analyzed using the Multi-Target Analysis Module of the InCell Analyzer 1000 236 Workstation Software (GE Healthcare). eGFP-reduction neutralization activity of the 237 238 serum samples was calculated by dividing the number of eGFP positive cells for each serum sample by the average number of eGFP positive cells in the no serum control 239 wells. 240

BRBV neutralization assay. A focus reduction neutralization assay (FRNT) was
 developed for BRBV. Vero E6 cells were seeded overnight in tissue-cultured treated 96 well plates (Corning). Heat-inactivated human or mouse sera were diluted 1:20 in DMEM SF media and subsequently serially diluted 3-fold to a final dilution of 1:14580. Next, an

equal volume of DMEM-SF containing 200 FFU of BRBV was added to each serum 245 dilution and incubated for 1 h at RT. The addition of the virus resulted in a final serum 246 dilution of 1:40 to 1: 29160. Next, the Vero E6 cells were washed once with PBS and the 247 antibody-virus complexes were transferred to cells and incubated for 1 h at 37°C. Each 248 serum sample and dilution was tested in duplicate and each assay included positive 249 250 (pooled convalescent sera from BRBV infected mice), negative serum, and no serum controls. After 1 h at 37°C, the cells were washed once with PBS and 100 µL of MEM 251 containing 2% FBS and 1% methylcellulose was added to each well. After 24 h at 37°C, 252 253 the cells were fixed by adding 100 µL of 10% Formalin on top of the overlay (final concentration 5% Formalin) for 1 h at RT. Subsequently, cells were washed with PBS 254 and the assay was developed as described above for the focus forming assay. The 255 256 percent inhibition of BRBV infection was calculated by dividing the number of foci in the test sample by the average number of foci in the no serum control wells. 257

258 **Statistical analysis.** Data were analyzed by using GraphPad Prism version 9.3.1 259 software. EC₅₀ and IC₅₀ values were calculated by using log (inhibitor) vs response in 260 variable slope (four parameters) fixing both bottom and top constrain at 0 and 100 261 respectively.

262 **RESULTS**

263 **Construction of a replication-competent VSV expressing BRBV GP.** Since 264 authentic BRBV is a biosafety level 3 (BSL3) pathogen, we sought to develop a tool to 265 study aspects of the BRBV lifecycle at reduced biocontainment. To do this, we replaced 266 the glycoprotein gene in a molecular clone of eGFP-expressing VSV with the GP gene of 267 BRBV (VSV-BRBV) (**Fig 1A**). VSV-BRBV was capable of robust eGFP expression in 268 Vero-CCL81 and grew to high titers (>10⁸ FFU/mL) with similar plaque size to VSV 269 containing its native glycoprotein (**Fig 1B, C**).

270 Development of humanized monoclonal antibodies against GP of BRBV. Elevento-twelve weeks-old C57BL/6 mice were immunized intramuscularly with inactivated 271 BRBV followed by a single intramuscular boost with rGP of BRBV 33 days later. Sera 272 were collected 21 and 5 days after the first and second immunization respectively (Fig 273 2A) and used to measure GP specific antibody responses by ELISA. Compared to the 274 primary immunization, mice boosted with rGP of BRBV showed ~6-fold increase in serum 275 antibody titer for binding to BRBV rGP (Fig 2B). Five days after the boost, the spleens 276 from one immunized and a control animal were isolated and processed for detection and 277 278 isolation of BRBV GP-specific B cells. Nearly 2% of the ASC B-cells (CD4⁻, CD19⁺, IqD^{Io}, CD95⁺, GL7⁻, CD138⁺) were specific for BRBV-GP (Fig 2C). No BRBV-GP specific ASC 279 B-cells were detected in the naïve control animal. The BRBV-GP labelled B cells were 280 281 then single cell sorted by FACS into 96-well plates containing lysis buffer. Amplification of VH, V κ , and V λ genes from a single B-cell sorted 96-well plate showed ~70% 282 283 productive V-domains (n= 66/94) which were later grouped into nine different clonal 284 groups based the identity of their V and J alleles and the CDR3 region. One representative

VH and VL gene from each clonal group were cloned into human IgG1 expression
vectors, transfected in HEK293 cells, and purified. These mAbs are further referred to as
BRBV-GP-A05, -A08, -A10, -B02, -B03, -B04, -E02, -E04, and -F07. Purified mAbs were
tested for specificity and affinity to rGP by ELISA (Fig 2D). All nine antibodies were
specific for BRBV-GP, three (BRBV-GP-A05, -A08, and -B02) of which demonstrated
binding affinity to BRBV rGP with an EC₅₀ < 500 ng/mL.

The mAbs were further evaluated in a FFA with BRBV for their ability to detect surface 291 expressed GP on infected cells. In cells infected with BRBV, only two of the nine tested 292 293 mAbs (B02, and E02) were able to detect the GP protein on the surface of infected cells and produce distinct foci in this assay (Fig 2E). The remaining seven mAbs were unable 294 to detect GP expression in BRBV-infected Vero E6 cells. Of the two mAbs, E02 produced 295 the most distinct and intense foci in the BRBV FFA (**Fig 2E**). This data combined with the 296 ELISA data (Fig 2D), demonstrate that we produced the first BRBV specific monoclonal 297 antibodies that can be used for diagnostic assays. 298

A rapid, eGFP-based neutralization assay for BRBV. To facilitate throughput and 299 reduce the costs associated with BSL3 work, we developed a rapid and high-throughput 300 301 eGFP-based neutralization assay using a replication competent BRBV-GP pseudotyped VSV that also expressed eGFP (VSV-BRBV). To demonstrate the utility of this virus, cells 302 were inoculated with 200 FFU of VSV-BRBV with or without sera containing neutralizing 303 304 antibodies against BRBV. After 8 h without serum, eGFP expression is clearly visible in a subset of the cells (Fig 3A, left panel). The addition of mouse sera obtained from naïve 305 306 C57BL/6 animals did not inhibit the infection and replication of VSV-BRBV and similar 307 number of eGFP positive cells were visible (Fig 3A, middle panel). In contrast, the

addition of serum collected 22 days after inoculation of C57BL/6 mice with 10^4 infectious units of BRBV, completely neutralized VSV-BRBV and no eGFP-positive cells were detected (**Fig 3A, right panel**). Analysis of the positive and negative control sera show a significant difference (*P* < 0.0001) in neutralization of VSV-BRBV (**Fig 3B**). Combined, these data show that VSV-BRBV can be used as a high-throughput alternative for live BRBV to detect BRBV neutralizing antibodies.

A total of 440 human serum samples were tested in the rapid VSV-BRBV based 314 neutralization assay at two different dilutions of the sera (1:20 and 1:60). The inhibition of 315 316 VSV-BRBV infection was normalized to the no serum control wells included in each assay. The vast majority of the sera did not neutralize VSV-BRBV at either the 1:20 or 317 1:60 dilution of the sera (Fig 3C). Interestingly, three human serum samples 318 demonstrated > 80% reduction in VSV-BRBV infection at both serum dilutions (Fig 3C). 319 In addition, 54 and 14 sera were identified as potentially positive (> 60%, but < 80%320 inhibition) at the 1:20 and 1:60 dilution of the sera respectively (Fig 3C). The 14 samples, 321 identified as potentially positive in 1:60 dilution, were also potentially positive in 1:20 322 dilution and selected for further testing in the BRBV FRNT assay together with 3 positive 323 324 samples.

Neutralization of BRBV by human serum samples. To confirm our findings and demonstrate neutralizing of live BRBV by antibodies in human sera, we developed a FRNT for BRBV using the BRBV-GP specific mAb (E02) described above. Sera collected from naïve mice was unable to neutralize BRBV and the number of foci was comparable to the no serum controls (**Fig 4A, left panel**). In contrast, convalescent sera from mice

infected with BRBV was able to potently neutralize live BRBV (Fig 4A, right panel). The
IC₅₀ for these sera ranged between 1:500 and 1:1350.

Next, the BRBV FRNT assay was used to test the 17 human serum samples that 332 previously demonstrated complete or partial neutralization of VSV-BRBV (Fig 3C). The 333 three serum samples that strongly inhibited (> 80% inhibition) VSV-BRBV also inhibited 334 BRBV in the FRNT assay (Fig 4B, left panel). The IC₅₀ values for these three serum 335 samples were 1:2631, 1:1259 and 1:938. The remaining 14 human serum samples that 336 partially inhibited VSV-BRBV infection (> 60%, but <80% inhibition) did not neutralize 337 338 BRBV in the FRNT assay (Fig 4B, middle panel). As a control we tested 19 human serum samples that did not neutralize VSV-BRBV. None of the 19 control sera were able 339 340 to inhibit BRBV infection and their IC_{50} values were at the limit of detection (1:40) (Fig **4B**, right panel). Collectively, these data demonstrate that BRBV infections occur in the 341 St Louis community and that the seroprevalence of BRBV neutralizing antibodies is 342 ~0.7%. 343

344 **DISCUSSION**

Here we defined the first seroprevalence of BRBV serum neutralizing antibodies in 345 human sera collected from the greater St. Louis Metropolitan area. We developed two 346 virus neutralization assays, a rapid VSV-BRBV eGFP based neutralization assay, and a 347 BRBV focus reduction neutralization assay, to systematically evaluate the presence of 348 BRBV neutralizing antibodies in human serum. These assays identified 3 (0.7%) human 349 sera that contained BRBV specific neutralizing antibodies. These finding indicate that the 350 incidence of BRBV infection in the St. Louis region in Missouri, US is higher than 351 352 previously expected based simply on confirmed cases that have been reported.

BRBV is classified as a BSL3 pathogen and needs specialized laboratories, training, 353 and equipment to work with. As such, limited labs in the US and around the world have 354 the capacity to work with live BRBV. To facilitate the testing of BRBV-GP specific 355 countermeasures and determine the seroprevalence of neutralizing antibodies in humans 356 and wildlife, we developed a rapid eGFP-based neutralization assay using replication-357 competent VSV expressing both eGFP and BRBV GP. This virus can be used at lower 358 biosafety containment levels (BSL2). Importantly, compared to previously described 359 360 methods such as PRNT, both the eGFP-based rapid assay and the BRBV FRNT can be used to evaluate BRBV neutralizing antibodies within three days. Thus the turnaround 361 362 time is greatly improved.

One of the major limitation of studying emerging pathogens is the lack of reagents such as mAbs, recombinant proteins, reporter viruses etc. This is the first report describing mAbs specific for GP of BRBV. Two of these mAbs were able to detect GP

expression on cells infected with BRBV. Unfortunately, these antibodies did not neutralize
 BRBV, suggesting they do not bind the receptor binding site of the virus [3].

BRBV and HRTV are classified as emerging infectious diseases that are transmitted 368 via ticks in the US. A previous study demonstrated a 0.9% seroprevalence of HRTV 369 specific neutralizing antibodies in northwestern Missouri, US, where human cases and 370 371 infected ticks have been identified [23]. Our study demonstrates a 0.7% seroprevalence of BRBV specific neutralizing antibodies in individuals in the St. Louis area. This is the 372 first time that BRBV neutralizing antibodies have been reported in individuals without a 373 374 prior history of BRBV infection. These data also suggest that the true infection burden of BRBV in humans is much higher than previously expected. The seroprevalence in this 375 cohort may underestimate the true infection rate and burden. First, our human serum 376 cohort is from the greater St. Louis area and is likely composed primarily of urban 377 populations that are less likely to be exposed to BRBV infected ticks. Future 378 seroprevalence studies with sera from individuals living in rural areas where BRBV 379 infection in ticks have been reported are needed. Second, the presence of detectable 380 levels of neutralizing antibodies is a relatively high threshold for determining prior infection 381 382 with any virus including BRBV. For example, there are many individuals previously infected with the influenza virus or severe acute respiratory syndrome coronavirus 2 383 384 (SARS-CoV-2) who have no detectable serum neutralizing antibodies. Moreover, the true 385 infection burden of BRBV in US could be underestimated due to lack of diagnostic testing, unknown virus geographical distribution, and unknown rate of asymptomatic infections. 386 387 Combined with the widespread distribution of the lone star tick and the reported presence 388 of BRBV-specific antibodies in North Carolina, we expect the true infection burden of

BRBV to be much higher than what was previously expected based on the number of
confirmed BRBV infections per year.

Three human sera showed the highest neutralization activity (> 80% inhibition) in the 391 VSV-BRBV eGFP-based assay. These same samples were confirmed positive for BRBV-392 specific neutralizing antibody by FRNT. These findings suggest that the rapid assay and 393 394 the BRBV FRNT are consistent in detecting the true seropositive samples and that our cut-off of 80% is rigorous. These two BRBV neutralization assays will expand our 395 knowledge of BRBV seroprevalence in humans and in wild animals. Previous studies 396 397 have shown that serum from white-tailed deer, raccoons, domestic dogs, horses, and eastern cottontails also contains BRBV neutralizing antibodies [12, 13]. The assays 398 developed in this study will facilitate additional testing of animal species in BRBV endemic 399 and non-endemic areas and help identify the breadth of host species affected by this 400 virus. 401

In conclusion, our study established two neutralization assays for BRBV and for the first time evaluated BRBV seroprevalence in a cohort of human sera. We found 3 people that were positive for BRBV neutralizing antibodies.

405

406 **ACKNOWLEDGEMENTS**

We thank Maxene Ilagan at Washington University School of Medicine High Throughput Center for supporting with imaging. This study was supported by NIH/NIAID grants R21 AI151170 and U01 AI151810. P.W.R. is supported by 1F31AI154710-01A1.

410

411

412 AUTHOR CONTRIBUTIONS

G.B. and P.W.R. designed experiments. G.B. performed the neutralization assays. H.H. and A.E. generated and tested the monoclonal antibodies. P.W.R. and S.P.J.W. generated and characterized the VSV-BRBV virus. Y.D. and D.F. generated the recombinant glycoproteins. D.W. collected human serum samples. A.C.M.B. obtained the funding. G.B., H.H., P.W.R., and A.C.M.B. wrote the manuscript, and all authors edited the final version.

Morens, D.M. and A.S. Fauci, Emerging Pandemic Diseases: How We Got to COVID-19. Cell,

419 **REFERENCES**

1.

420

421 2020. 182(5): p. 1077-1092. 422 2. Bricker, T.L., et al., Therapeutic efficacy of favipiravir against Bourbon virus in mice. PLoS Pathog, 423 2019. 15(6): p. e1007790. 424 Bai, C., et al., Postfusion structure of human-infecting Bourbon virus envelope glycoprotein. J 3. 425 Struct Biol, 2019. 208(2): p. 99-106. 426 4. Jones, L.D., et al., Immune protection conferred by the baculovirus-related glycoprotein of 427 *Thogoto virus (Orthomyxoviridae).* Virology, 1995. **213**(1): p. 249-53. 428 5. Kosoy, O.I., et al., Novel thogotovirus associated with febrile illness and death, United States, 429 2014. Emerg Infect Dis, 2015. 21(5): p. 760-4. 430 6. Miller, M. Bourbon Virus Now Listed as Emerging Illness — New Case in St. Louis County. 2018 431 [cited 2021 11/10/21]; Available from: 432 https://www.emissourian.com/local news/county/bourbon-virus-now-listed-as-emergingillness-new-case-in-st-louis-county/article 5d67a0e6-bf55-5cfb-9e6c-9b73896fafad.html. 433 434 7. Lambert, A.J., et al., Molecular, serological and in vitro culture-based characterization of 435 Bourbon virus, a newly described human pathogen of the genus Thogotovirus. J Clin Virol, 2015. 436 73: p. 127-132. 437 8. Savage, H.M., et al., Bourbon Virus in Field-Collected Ticks, Missouri, USA. Emerg Infect Dis, 2017. 438 **23**(12): p. 2017-2022. 439 9. Savage, H.M., et al., Surveillance for Tick-Borne Viruses Near the Location of a Fatal Human Case 440 of Bourbon Virus (Family Orthomyxoviridae: Genus Thogotovirus) in Eastern Kansas, 2015. J Med 441 Entomol, 2018. 55(3): p. 701-705. 442 Godsey, M.S., et al., Experimental Infection of Amblyomma americanum (Acari: Ixodidae) With 10. 443 Bourbon Virus (Orthomyxoviridae: Thogotovirus). J Med Entomol, 2021. 58(2): p. 873-879. 444 Savage, H.M., et al., Surveillance for Heartland and Bourbon Viruses in Eastern Kansas, June 11. 445 2016. J Med Entomol, 2018. 55(6): p. 1613-1616. 446 Jackson, K.C., et al., Bourbon Virus in Wild and Domestic Animals, Missouri, USA, 2012-2013. 12. 447 Emerg Infect Dis, 2019. 25(9): p. 1752-1753. 448 13. Komar, N., et al., Indirect Evidence of Bourbon Virus (Thogotovirus, Orthomyxoviridae) Infection 449 in North Carolina. N C Med J, 2020. 81(3): p. 214-215. 450 14. Case, J.B., et al., Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent 451 VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. Cell host & microbe, 2020. 28(3): p. 475-452 485.e5. 453 Stevens, J., et al., Structure and receptor specificity of the hemagglutinin from an H5N1 influenza 15. 454 virus. Science, 2006. 312(5772): p. 404-10. 455 Wang, X., et al., A herpesvirus encoded Qa-1 mimic inhibits natural killer cell cytotoxicity through 16. 456 CD94/NKG2A receptor engagement. Elife, 2018. 7. 457 17. von Boehmer, L., et al., Sequencing and cloning of antigen-specific antibodies from mouse 458 memory B cells. Nature Protocols, 2016. 11(10): p. 1908-1923. 459 18. Brochet, X., M.P. Lefranc, and V. Giudicelli, *IMGT/V-QUEST: the highly customized and* 460 integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res, 461 2008. 36(Web Server issue): p. W503-8. 462 19. Giudicelli, V., X. Brochet, and M.P. Lefranc, IMGT/V-QUEST: IMGT standardized analysis of the 463 immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harb Protoc, 464 2011. 2011(6): p. 695-715.

- 465 20. Ho, I.Y., et al., *Refined protocol for generating monoclonal antibodies from single human and* 466 *murine B cells*. J Immunol Methods, 2016. **438**: p. 67-70.
- 467 21. Davis, C.W., et al., Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection.
 468 Cell, 2019. 177(6): p. 1566-1582.e17.
- Smith, B.K., et al., Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, *Missouri, USA.* mSphere, 2021. 6(1).
- 471 23. Lindsey, N.P., et al., *Seroprevalence of Heartland Virus Antibodies in Blood Donors, Northwestern*472 *Missouri, USA.* Emerg Infect Dis, 2019. 25(2): p. 358-360.

473

474 **FIGURE LEGENDS**



475

Figure 1

Figure 1: Generation of a replication-competent VSV expressing eGFP and BRBV GP. (A) Genome schematic. Genes encoded by each virus are to scale (except Le – Leader and Tr – Trailer) and are indicated by eGFP (enhanced green fluorescent protein), N (nucleoprotein), P (phosphoprotein), M (matrix protein), G or GP (glycoprotein), and L (large protein or polymerase). Glycoprotein gene length excludes the stop codon. (B) Vero-CCL81 were infected with VSV or VSV-BRBV at an MOI of 1 images were acquired 6 hours post infection (hpi). (C) Representative plaque assay of VSV or VSV-BRBV on Vero-CCL81 cells. Images were acquired 24 hpi.



Figure 2

Figure 2: Generation and characterization of humanized monoclonal antibodies against 484 BRBV GP. (A) Immunization regimen. 11-12 weeks old C57BL/6 mice were immunized 485 intramuscularly with 500 ng BPL-inactivated BRBV, followed by boosting with 5 µg of rGP of 486 487 BRBV 33 day later. Sera was collected at days 21 and 38. Spleens were harvested five days post boost (day 38) (B) IgG serum Ab ELISA for rGP of BRBV for naïve and immunized mice at days 488 489 21 and 38. Results are average of two independent experiments. (C) Representative plots of BRBV-GP specific ASC B-cells (CD4⁻, CD19⁺, IgD^{Io}, CD95⁺, GL7⁻, CD138⁺, BRBV-GP⁺ live singlet 490 lymphocytes) in naïve mice (top) and BRBV-immunized mice (bottom) (D) ELISA measuring 491 binding of nine mAbs to rGP of BRBV. Each line is a different antibody and the results are the 492 average of two independent experiments. (E) Binding of mAb B02 and E02 to BRBV-infected 493 cells. Vero cells were infected with ~100 infectious units of BRBV for 24 h, fixed with 5% formalin, 494

483

- and virus-infected cells were visualized by incubating the cells with 2-3 µg/mL of mAbs B02 and
- 496 E02, or a control. Images are representative of 2 experiments.

497

498



Figure 3

499

500

501 Figure 3: Development of a rapid eGFP-based BRBV neutralizing assay. (A) Effective 502 neutralization of VSV-BRBV by BRBV-neutralizing antibodies. Monolayers of Vero cells incubated 503 for 8 h with VSV-BRBV, expressing eGFP, in the presence of mouse serum-containing BRBV 504 neutralizing antibodies (positive control), control mouse serum, or no serum were visualized with 505 DAPI (blue color). VSV-BRBV infected cells were visualized by the expression of GFP from the 506 VSV genome. Representative images of the no serum (left), negative serum (middle), and positive 507 serum (right) controls are shown at 4x magnification. (B) Normalized VSV-BRBV neutralization (% inhibition compared to no serum control) of the positive and negative control sera. Each symbol 508 509 is an individual mouse serum sample (n = 15 negative control, n = 5 positive control) (C) Normalized VSV-BRBV infection (% inhibition compared to no serum control) of 440 human 510 511 serum samples at a 1:20 (left panel) and 1:60 (right panel) dilution of the sera. Each symbol is a serum sample. The dotted lines represent the cut-offs for 60% and 80% inhibition. 512



513

514

Figure 4: Detection of serum neutralizing antibodies against BRBV in human serum 515 516 samples. A focus reduction neutralization test (FRNT) was developed for BRBV. Serially diluted heat-inactivated human or mouse sera (starting at 1:40 dilution) was incubated for 1 h with 100 517 focus forming units of BRBV prior to adding it to Vero cells. One h later, the inoculum was 518 519 removed, the cells were overlaid with 1% methylcellulose, and incubated for 24 h. Clusters of 520 infected cells (foci) were visualized using the E02 mAb as described in the Materials and Methods 521 section. The number of foci are normalized to no serum controls. (A) Left. FRNT with serum from mock-infected control animals. No BRBV neutralizing activity was detected in the negative control 522 523 sera. Right. FRNT demonstrating virus-neutralizing activity in convalescent serum collected from 524 C57BL/6 mice 22 days after inoculation with 10⁴ PFU of BRBV. Neutralization of BRBV was detected in all five mouse serum samples. (B) FRNT on human serum samples with distinct 525

- neutralizing activities in the rapid assay. Human serum samples showing complete neutralization
- 527 (0-20%, *left*), partial neutralization (20-40%, middle), or no neutralization (100%, right) in the VSV-
- 528 BRBV rapid assay were tested by FRNT. Three human sera were able to neutralized BRBV by
- 529 FRNT.